Company intelligence / Profile preview

Precipio

New Haven, Connecticut, United Statesprecipiodx.com ↗

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Precipio offers commercialized proprietary diagnostic products and services for hematopathology and blood cancer testing. Their platforms are used by clinical laboratories and physicians to improve accuracy and efficiency in diagnosing blood cancers. The company has demonstrated strong year-over-year revenue growth in both its product sales and pathology services divisions, with recent regulatory milestones such as MolDx approval for NGS testing enabling Medicare billing.

Therapeutic areas: HematologyOncology
Modalities: Diagnostic test (IV‑Cell cell culture media)Diagnostic panel (HemeScreen genetic panels)PCR-based technology (ICE COLD-PCR)
Industry: Molecular Diagnostics

Partnerships

Not explicitly listed; the company provides biomarker testing and clinical project services to bio-pharma customers.

Beyond the preview

Go deeper on Precipio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precipio.

Explore the full profile